A National Cancer Institute-designated Comprehensive Cancer Center

Make an appointment: 800-826-HOPE

Clinical Immunobiology Correlative Studies Laboratory

Clinical Immunobiology Correlative Studies Laboratory
Overview
The Clinical Immunobiology Correlative Studies laboratory (CICSL) was founded in 2004, based on an identified need for a central laboratory dedicated to the development and implementation of cutting–edge immune correlative studies to support clinical trial protocols in the Cancer Center.
The CICSL has developed and has available a variety of assays that are based on molecular, flow Cytometry, molecular, functional, and biochemical platforms; the laboratory operates under principles of Good Laboratory Practice (GLP).
The laboratory also houses as the Quality Control (QC) unit for the Cell Therapeutics Program within HCT, developing and performing characterization and release tests for therapeutic cell products.
 
Objective
The research objective of the Clinical Immunobiology Correlative Studies Laboratory (CICSL) is to support Cancer Center investigators through the development, validation, and implementation of highly quantitative immune correlative studies that will be applied to evaluate the efficacy of immunotherapy-based and other clinical trials at the City of Hope. CICSL assay platforms are also available to support translational projects that utilize in-vitro and model systems.
 
Importance
  • The ability to quantitatively evaluate what has happened immunologically and molecularly in patients after receiving treatment is critical in order to obtain insight on why a particular regimen did or did not work, to guide the rational design of ultimately more effective immunotherapy strategies
  • Correlative studies that are well designed and performed are increasingly being viewed as critical components to clinical trials, and standards of quality such as assay qualification/validation, statistical significance of results, and GLP lab environment will be required for results to be published in top-tier peer reviewed publications
  • Since a comprehensive understanding of the effect of treatment on patients is in most circumstances lacking, there is a strong rationale to develop and apply a broad series of platforms and assays to evaluate samples and specimens obtained from patients enrolled in clinical protocols
 
Diagram illustrating the need for broad and comprehensive
correlative assays
 
The laboratory has developed a wide variety of platforms and assays.
 
Specifically:
Flow Cytometry:
Characterization of immune cell activation/differentiation/homing status
Absolute count determination and quantification of immune cell subsets
Analysis of immune cell effector phenotypes (ICC, CD107)
MHC tetramer analysis
Intracellular cytokine staining.

Molecular:
Q-RT-PCR-based quantification of immune cell subsets (including Treg cells)
Q-RT-PCR-based quantification of mRNA levels for immune effector genes
Q-PCR-based quantification of adoptively transferred cells
Vb spectratyping

Biochemistry:
Simultaneous quantification of multiple cytokine/chemokine/growth factors in serum, tissue samples, tissue culture using Luminex bead array
Simultaneous quantification of multiple phosphoproteins in tissue culture and tissue samples using Luminex bead array
 
Cell-based:
CD8 and NK cytolysis bioassays
Cell proliferation assays
Blood processing, PBMC/serum/plasma isolation, freezing, and storage
In-vitro CD8 and CD4 T cell culture
 
Last updated: 06/30/2008
 

Abstract for Grants

The City of Hope Clinical Immunobiology Correlative Studies laboratory (CICSL) is a Shared Resource for the City of Hope Comprehensive Cancer Center. The laboratory occupies approximately 1000 square feet of laboratory space in the Shapiro building (rooms 1002, 1044, and 1045). This space includes a 275 square foot tissue culture area, a 275 square foot area dedicated to qPCR and ELISA, a 250 square foot room dedicated to liquid nitrogen, -80°, and -20° C storage, and a 200 square foot room housing dedicated to Luminex equipment. CICSL laboratory operations are guided by GLP principles of operation, with all possible equipment 21 CFR part 11 compliant.
 
The CICSL includes state-of-the-art equipment for monitoring immune responses to cancer therapy. Specific equipment includes a fully automated microplate based multi-detection reader capable of reading fluorescence intensity, time-resolved fluorescence, high-performance luminescence (flash and glow), and absorbance, a Luminex FLEXMAP 3D bead array reader, a Luminex BioPlex™-HTX bead array reader, two MJR Chromo 4™ Q-PCR machine, and a Guava PCA-96 analytical cell counter and analyzer. The CICSL additionally makes use of access to instruments within the City of Hope Analytical Flow Cytometry Core, including a Beckman Coulter Gallios three-laser flow cytometer capable of evaluating fluorescence in ten distinct colors, and analytical cell sorters.
 
Current assays within the capabilities of the laboratory include:
 
  • Flow Cytometry: Characterization of immune cell activation/differentiation/homing status; analysis of immune cell effector phenotypes and functionality (ICC, CD107); absolute count determination and quantification of immune cell subsets.
 
  • Molecular: quantitative real-time PCR-based quantification of immune cell subsets (including Treg cells) and mRNA levels for immune effector genes; qPCR-based quantification of adoptively transferred cells; Vβ spectratyping.
 
  • Biochemical: Quantification of multiple biomarkers and analytes in serum, plasma, tissue samples and cell culture medium using Luminex bead array and ELISA platforms. These analytes include cytokines and chemokines, growth factors, endocrine markers and hormones, cardiovascular markers, bone metabolism markers, cell signaling molecules, and cancer markers.
 
  • Cell-based: Blood processing; PBMC/serum/plasma isolation; freezing, and storage; CD8 and NK cytolysis bioassays.
 

Assays

In general, the CICSL develops assay platforms that can be applied to multiple clinical studies. Please contact the CICSL director if you are interested in having the laboratory develop an assay not listed below.
 
Current Available Assays and Procedures
 
Flow Cytometry
Characterization of immune cell activation/differentiation/homing status
Analysis of immune cell effector phenotypes (ICS, CD107 degranulation)
Absolute count determination and quantification of immune cell subsets
MHC:tetramer analyses
Proliferation assays (CFSE)
 
Molecular
Nucleic acid (DNA, RNA) isolation
cDNA synthesis
Q-RT-PCR-based quantification of immune cell subsets
Q-RT-PCR-based quantification of mRNA levels for immune and other factors
Q-PCR-based quantification of adoptively transferred cells
Vβ spectratyping
 
Biochemical
 
i. Luminex X-MAP bead array-based
Quantification of multiple cytokine/chemokine/growth factors in serum, tissue samples, tissue culture
ii. ELISA-based
Quantification of cytokine/chemokine/growth factors in serum, culture, tissue samples
iii. Quantification of phosphorylation status of intracellular signal transduction molecules, transcription factors by Luminex X-MAP bead array
 
Cell-based
Blood processing, PBMC/serum/plasma isolatio
 

Equipment

The CICSL is equipped with state-of-the-art equipment to allow for the evaluation and monitoring of immune responses in patients post-immunotherapy. Specific equipment available in the laboratory include:

 

Luminex FLEXMAP 3D System (Luminex multi-bead array)

View Luminex FlexMAP3D System website


The new FLEXMAP 3D® system takes Luminex xMAP® technology to three dimensions. The FLEXMAP 3D system combines differentially dyed fluorescent microsphere sets with an innovative instrument design to allow multiplexing of up to 500 unique assays within a single sample, both rapidly, and precisely. The FLEXMAP 3D accommodates 96 and 384-well formats for enhanced sample volume flexibility and increased throughput. Sample plate heating control also allows the user to run thermally sensitive applications such as nucleic acids.The FLEXMAP 3D system works in the same basic manner as the Luminex® 100TM analyzer. Mixtures of internally dyed microspheres are used in an assay, each having been prepared to bind to a specific analyte of interest. After the assay has been performed the mixture of microspheres is aspirated into the system and then each individual microsphere is individually excited by a red and green laser. Each microsphere is impregnated with different amounts of three internal dyes. All dyes excite at the same red laser wavelength, but fluoresce at three separate wavelengths. Monitoring the relative intensity of the three signals allows the system to discriminate up to 500 different microsphere sets. The green laser is then used to excite the reporter molecules, normally in the form of phycoerythrin, and the resulting fluorescence is measured to determine the amount of analyte present.

 

 

Bio-Rad Bio-Plex HTF System (Luminex multi-bead array)
View Bio-Rad Bio-Plex System website

The Bio-Rad Bio-Plex 100 allows for the simultaneous assay of up to 100 distinct proteins in a single well of a microtiter plate, using very small sample volumes. The system delivers fast and cost-effective bioassay results on many assay formats including cytokines, immunoassays and enzymatic assays, nucleic acid assays, receptor-ligand assays, and phosphorylation assays. The Bio-Plex utilizes Luminex xMAP® technology which is based on the use of 100 distinctly color-coded microspheres. Each microsphere set can be coated with a reagent specific to a particular bioassay, for example individual anti-cytokine antibodies, allowing the capture and specific detection of multiple distinct cytokines from a sample in a single microplate well. Within the Luminex 100 compact analyzer, lasers excite the internal dyes that identify each microsphere particle, and also any reporter dye captured during the assay.
 
MJR Chromo 4™ Thermal Cycler
The MJR Chromo 4 is a Q-PCR instrument that allows for the quantitation of specific nucleic acid sequences in samples. The instrument is capable of excitation and detection in four different channels allowing for PCR multiplex analyses, has a linear dynamic range of up to ten orders of magnitude, and can detect a single copy of initial template in samples.
 
BMG FLUOstar OPTIMA
View BMG FLUOstar OPTIMA website
The FLUOstar OPTIMA is a fully automated microplate based multi-detection reader which incorporates five different measurement principles: fluorescence intensity, time-resolved fluorescence, high-performance luminescence (flash and glow), and absorbance. It is designed for the widest possible range of non-radioactive labeled applications, including immunoassays (ELISA), Ca2+ Measurements (e.g. Ca2+ Flux with Fura-2 or Indo-1), enzyme activity, cell toxicity, proliferation and viability, cytotoxicity and ATP quantification. The instrument covers a wavelength range from 240 to 740 nm and can read all plate formats from six up to 384-well plates in all four measurement modes. The versatile optical system allows instant switching from top to bottom reading. Temperature-regulated heating plates above and below the entire plate movement area provide uniform incubation up to 60°C. The instrument is equipped with a single syringe pumps. Injection speed and timing can be adjusted as is appropriate for particular assays. Delivery volume is adjustable between 3-350 µL in 1µL increments and is individually adjustable for each well allowing control of dilution schemes, concentration ranges, etc.
 
Tissue Culture/LN2 Storage
The CICSL is equipped with class II type A2 bio-safety cabinets and CO2 incubators to allow the culture and analysis of immune cell subsets, as well as a controlled rate-cell freezer and liquid N2 freezers for long term storage of biological samples.
 

Using the Facility

Scheduling
Please contact the core director to schedule an initial consultation regarding the correlative studies you are proposing for your clinical trial. A research plan will then be assembled by the director and submitted to the principal investigator for approval. A lead time of three to six months is generally required for protocol development.
 
Note: Equipment operation is restricted to qualified CICSL personnel.
 
Quality Control
Protocol development, instrumentation, reagent, and technical quality control in the CICSL will be guided by GLP principles of operation. To the extent possible, all CICSL equipment is compliant with 25 CFR part 11 guidelines.
 

Immunobiology Correlative Studies Team

Research Shared Services

City of Hope embodies the spirit of scientific collaboration by sharing services and core facilities with colleagues here and around the world.
 

Recognized nationwide for its innovative biomedical research, City of Hope's Beckman Research Institute is home to some of the most tenacious and creative minds in science.
City of Hope is one of only 41 Comprehensive Cancer Centers in the country, the highest designation awarded by the National Cancer Institute to institutions that lead the way in cancer research, treatment, prevention and professional education.
Learn more about City of Hope's institutional distinctions, breakthrough innovations and collaborations.
Support Our Research
By giving to City of Hope, you support breakthrough discoveries in laboratory research that translate into lifesaving treatments for patients with cancer and other serious diseases.
 
 
 
 
Media Inquiries/Social Media

For media inquiries contact:

Dominique Grignetti
800-888-5323
dgrignetti@coh.org

 

For sponsorships inquiries please contact:

Stefanie Sprester
213-241-7160
ssprester@coh.org

Christine Nassr
213-241-7112
cnassr@coh.org

 
CONNECT WITH US
Facebook  Twitter  YouTube  Blog
 
NEWS & UPDATES
  • For breast cancer survivors, a common worry is a recurrence of their cancer. Currently, these patients are screened with regular mammograms, but there’s no way to tell who is more likely to have a recurrence and who is fully cleared of her cancer. A new blood test – reported in Cancer Research, a journal of the...
  • Metastasis — the spreading of cancer cells from a primary tumor site to other parts of the body — generally leads to poorer outcomes for patients, so oncologists and researchers are constantly seeking new ways to detect and thwart this malicious process. Now City of Hope researchers may have identified a substa...
  • Deodorant, plastic bottles, grilled foods, artificial sweeteners, soy products … Do any of these products really cause cancer? With so many cancer myths and urban legends out there, why not ask the experts? They can debunk cancer myths while sharing cancer facts that matter, such as risk factors, preventi...
  • Cancer risk varies by ethnicity, as does the risk of cancer-related death. But the size of those differences can be surprising, highlighting the health disparities that exist among various ethnic groups in the United States. Both cancer incidence and death rates for men are highest among African-Americans, acco...
  • George Winston, known worldwide for his impressionistic, genre-defying music, considers music to be his first language, and admits he often stumbles over words – especially when he attempts languages other than English. There’s one German phrase he’s determined to perfect, however: danke schön. Winston thinks h...
  • Few decisions are more important than those involving health care, and few decisions can have such lasting impact, not only on oneself but on relatives and loved ones. Those choices, especially, should be made in advance – carefully, deliberately, free of pain and stress, and with much weighing of values and pr...
  • Using a card game to make decisions about health care, especially as those decisions relate to the end of life, would seem to be a poor idea. It isn’t. The GoWish Game makes those overwhelming, but all-important decisions not just easy, but natural. On each card of the 36-card deck is listed what seriously ill,...
  • Young adults and adolescents with cancer face unique challenges both during their treatment and afterward. Not only are therapies for children and older adults not always appropriate for them, they also must come to terms with the disease and treatment’s impact on their relationships, finances, school or ...
  • Breast cancer is the most common cancer, other than skin cancer, among women in the United States. It’s also the second-leading cause of cancer death, behind lung cancer. In the past several years, various task force recommendations and studies have questioned the benefits of broad screening guidelines fo...
  • Paternal age and the health effects it has on potential offspring have been the focus of many studies, but few have examined the effect parental age has on the risk of adult-onset hormone-related cancers (breast cancer, ovarian cancer and endometrial cancer). A team of City of Hope researchers, lead by Yani Lu,...
  • Hormone therapy, which is prescribed to women for relief of menopausal symptoms such hot flashes, night sweats and vaginal dryness, has recently seen a decline in popularity (and use) due to its link to an increased risk of breast and endometrial cancer. But City of Hope researchers have found that menopausal h...
  • Myeloproliferative neoplasms can’t be narrowed down to a single cancer, but they can be described by a defining characteristic: too many blood cells. The diseases bring with them a host of frustrating, potentially life-altering symptoms, and management of the diseases and their symptoms is crucial. An upcoming ...
  • More than 18,000 researchers, clinicians, advocates and other professionals will convene at the 105th American Association for Cancer Research (AACR) annual meeting taking place in San Diego from April 5 to 9. With more than 6,000 findings being presented over this five-day period, the amount of information can...
  • Cancer of the prostate is the No. 2 cancer killer of men, behind lung cancer, accounting for more than 29,000 deaths annually in this country. But because prostate cancer advances slowly, good prostate health and early detection can make all the difference. Many prostate cancer tumors don’t require immedi...
  • Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer’s ability to resist treatment, renderi...